CD163 and psoriasis: Biomarkers like CD163(+) M2 macrophages are associated with disease progression, while treatments that enhance M2 macrophage function, such as PSORI‐CM02 and Treg‐of‐B cell therapies, show potential in alleviating psoriasis symptoms.